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1. ABSTRACT   
Introduction: Cyclooxygenase-2 (COX-2) is overexpressed in several malignancies and is 
implicated in breast cancer progression. Objectives: We investigated whether changes in COX-2 
expression may affect epithelial-to-mesenchymal transition (EMT) and then invasive potential of 
human breast cancer cells, in relationship with hypoxia. COX-2-null MCF-7 human breast cancer 
cells, MCF-7 cells transiently expressing COX-2, and COX-2-expressing MDA-MB-231 cells were 
employed. Results: COX-2 overexpression resulted in down-regulation of E-cadherin and ß-
catenin, up-regulation of vimentin, N-cadherin and SNAI1, suggesting EMT occurrence. COX-2-
overexpressing MCF-7 cells were also characterized by increased invasiveness and release of 
matrix-metalloproteinase-9. The above-mentioned characteristics, homologous to those detected in 
highly invasive MDA-MB-231 cells, were reverted by treatment of COX-2-overexpressing MCF-7 
cells with celecoxib, a COX-2 specific inhibitor, partly through the inhibition of COX-2-related 
intracellular generation of reactive oxygen species. Hypoxia further exacerbated COX-2 expression, 
EMT changes and invasive ability in both COX-2-overexpressing MCF-7 cells and MDA-MB-231 
cells. Finally, immunohistochemistry performed on samples from normal and neoplastic human 
breast tissues revealed that COX-2-positive malignant cells were also positive for EMT-related 
antigens, HIF-2α and the oxidative stress marker heme-oxygenase. Conclusions: These findings 
support the existence of a direct link between COX-2 overexpression, EMT and invasiveness in 
human breast cancer cells, emphasizing the role of hypoxic microenvironment. 
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2. INTRODUCTION 
Breast cancer is a leading cause of death in females in the western world [1]. In the last decade 
several studies have outlined a link between the pathogenesis of breast cancer and the expression of 
cyclooxygenase-2 (COX-2) [2-5]. Deregulation of COX-2 expression leads to an increased 
abundance of prostaglandin E2 (PGE2), which can potentially affect most of key processes in cancer 
development, including proliferation, resistance to apoptosis, angiogenesis, immune suppression 
and invasion [6,7].  
COX-2 expression in invasive breast cancer as well as its crucial role in the ability of carcinoma in 
situ to progress towards invasive breast cancer has been widely documented and likely depends on 
COX-2 role in the destruction of the basal membrane and in the formation of new blood vessels 
allowing tumour growth [8]. Thus, COX-2 expression has been associated with negative prognosis 
and disease progression [9].  
According to literature, also the tumour microenvironment can play a crucial role in cancer 
progression [10], with fluctuation of hypoxia and nutrient deprivation being prominent features 
which can lead  to cellular adaptation. Cell adaptation can favour survival of cancer cells and can 
give rise to heterogeneity and selection of resistant clones, then resulting in a more malignant 
phenotype [11]. Along these lines, hypoxia is indeed a common feature of solid malignant tumours 
and is predominantly caused by abnormal vascularization of the rapidly growing tumour mass, with  
areas of low oxygen pressure being heterogeneously distributed [12,13].  
The key regulators of cellular responses to hypoxia are hypoxia-inducible factors  (HIFs) which are 
known to activate and/or regulate target genes involved in a number of different cellular processes, 
including proliferation, angiogenesis and epithelial-to-mesenchymal transition (EMT), all linked to 
malignant progression [11,14,15]. 
EMT has emerged in recent years as a fundamental biological process, leading epithelial cells to 
lose their polarization and specialized junctional structures, to undergo cytoskeleton reorganization, 
and to acquire morphological and functional features of mesenchymal-like cells [16-19].   
 
4 
One of the most convincing evidence for EMT in the clinical scenario involves the loss of selected 
epithelial features in cancer cells, typically involving the adherent junction proteins E-cadherin, α- 
and β-catenin, and cytokeratins, resulting in destabilisation of cell-cell contacts and detachment of 
cells from surrounding ones [20]. Concomitantly, a number of mesenchymal markers are increased 
in their expression, including N-cadherin, vimentin, fibronectin, matrix metalloproteinases as well 
as the transcriptional regulator of the mesenchymal phenotype SNAI1 [21,22] . 
Along these lines, it has been proposed that COX-2 may be induced by the hypoxic 
microenvironment in colorectal and lung cancer cells via HIF-1-dependent mechanisms  [23,24], an 
event that may enhance cell motility and invasion. Although the mechanisms underlying this 
scenario are still not entirely clear, hypoxia-related COX-2 up-regulation is associated with an 
increase in PGE2 levels [24], suggesting a role for PGE2 in the promotion of cell survival under 
hypoxic conditions, a property that tumour cells acquire in order to propagate and progress [15].  
The present study sought to investigate the influence of the COX-2/PGE2 pathway on the behaviour 
of breast cancer cells, focusing the attention on the hypothesis that COX-2 up-regulation may be 
linked to EMT and, therefore, critical for motility, invasion, and metastasis. In order to explore this 
hypothesis we created a model of human breast cancer cells overexpressing COX-2, by means of 
transient transfection of human COX-2 cDNA into the COX-2 null [25], poorly invasive and 
estrogen-dependent MCF-7 human breast cancer cell line. Furthermore, COX-2 expression in 
human breast cancer malignancy was preliminarly examined in a panel of clinical specimens from 
human breast cancers.  
 
3. MATERIALS AND METHODS 
3.1 Materials and reagents 
Mouse monoclonal antibody for -actin and anti-goat Cy3-conjugated secondary antibody were 
purchased from Sigma Chemical Co (MO, USA). Rabbit polyclonal antibodies for p-Akt, p-
ERK1/2, N-cadherin, E-cadherin, SNAI1, HIF-1α, β-catenin, vimentin and HRP-conjugated 
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secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (CA, USA). Rabbit 
polyclonal antibodies for HO-1 and COX-2 were from Stressgen Biotechnologies (British 
Columbia, Canada) and Cayman Chemical (Ann Arbor, MI, USA), respectively. Rabbit polyclonal 
antibody for HIF-2α was from Novus Biologicals (Cambridge, UK). Anti-rabbit Cy3-conjugated 
secondary antibody was from GE Healthcare Europe GmbH (Milano, Italy). Boyden chambers were 
from Neuro Probe Inc. (MD, USA). The X-treme GENE HP DNA transfection reagent was from 
Roche Diagnostics (Mannheim, Germany). Celecoxib was obtained from Sequoia Research 
Products Ltd (Pangbourne, UK), solubilized in dimethyl sulfoxide (DMSO) and used at a final 
concentration of DMSO that never exceeded 0.1%. The enhanced chemiluminescence reagent and 
nitrocellulose membrane (Hybond-C extra) were from GE Healthcare Europe GmbH (Milano, 
Italy). All other reagents were from Sigma Chemical Co (MO, USA) . 
3.2 Cell lines and culture conditions 
MCF-7 and MDA-MB-231 human breast cancer cells, from American Type Cell Culture (ATCC, 
Manassas, VA, USA), were grown and maintained in DMEM medium supplemented with 10% 
foetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 25 μg/ml amphotericin B. 
Cells were cultured at 37 °C in a humidified incubator with 5% CO2 and 95% air, and regularly 
examined using inverted microscope. 
In most of the experiments cells were seeded at 3×10
4
 cells/cm
2
 density and cultured in normoxic 
conditions for 24 h to allow them to adhere. In experiments designed to evaluate the role of 
hypoxia, MCF-7 cells, COX-2-overexpressing MCF-7 cells and MDA-MB-231 cells were first 
seeded in normoxic conditions to obtain the desired subconfluence level (65-70%) and then 
incubated under strictly controlled hypoxic conditions (3% O2) for 2 h, 4 h, 8 h and 24 h [21]. 
3.3 Transient expression of COX-2 
For transfections, the COX-2 cDNA cloned in the pCMV-Sport6 (Source Bioscience, Nottingham, 
UK) was used. MCF-7 cells were seeded onto 6-well plates; after 24 h, the cells were transfected 
with 2 µg DNA/well of either the plasmid encoding the wild-type COX-2, or with the empty vector, 
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using X-treme GENE HP DNA transfection reagent according to manufacturer’s recommendations. 
Cells were allowed to grow 24 or 48 h after transfection before harvesting for the assays. 
3.4 Detection of prostaglandin E2 
Cells plated at 6.5×10
5
 cells in F25 flasks were grown in 10% heat-inactivated FBS for 24 h, 
washed with PBS and serum starved for 24 h. Cells were exposed for 30 min to 10 μM sodium 
arachidonate (Sigma Chemical Co, MO, USA);  then, the  medium was collected from culture plates 
to evaluate PGE2 production using an Enzyme Immunoassay (EIA) according to manufacturer’s 
instructions (Cayman Chemical, Ann Arbor, MI).  
3.5 Viability assay 
Cells were seeded in 12-well culture plates and treated as required. Cells were incubated with 
trypan blue solution (0.5% in NaCl) for 5 min to assess cell viability. Finally, cells were transferred 
to a Bürker chamber and counted by light microscope. Dead cells were defined as those stained 
with the dye.  
3.6 Total extracts  
Cells were seeded in 75 cm
2
 plates and treated as required. Cells were then re-suspended in lysis 
buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid 
(EDTA), 0.1 mM phenylmethyl-sulfonyl fluoride (PMSF), 0.05% aprotinin, 0.1% Igepal and then 
incubated
 
for 30 min at 4 °C. The suspension was centrifuged
 
for 25 min at 12000 rpm and the 
supernatant was saved as the total extract. Protein levels were measured using a commercially 
available assay (Protein Assay Kit 2, Bio-Rad Laboratories, Milano, Italy) with bovine serum 
albumin as a standard. 
3.7 Western blotting 
Total extracts were
 
then subjected to sodium dodecyl sulphate-polyacrylamide
 
gel electrophoresis 
on 12, 10 or 7.5% acrylamide gels (Bio-Rad Laboratories, Milano, Italy). The blots
 
were incubated 
first with desired primary antibody and then with peroxidase-conjugated anti-mouse or anti-rabbit 
antibodies
 
in Tris-buffered saline-Tween containing 2% (wt/vol) non-fat
 
dry milk, and developed
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with the enhanced chemiluminescence reagent. Band intensities were quantified by densitometry 
(VersaDoc Imaging System 3000, Bio-Rad Laboratories, Milano, Italy) and the expression of
 
proteins was reported as a proportion of β-actin protein expression to monitor gel loading. 
3.8 Morphological analysis 
For indirect immunofluorescence, cells were seeded on 6-well culture plates, allowed to adhere for 
24 h and then treated. After treatment, the cells were fixed and permeabilized with 
methanol/acetone (1:1, v/v). Cells were then incubated with polyclonal antibodies for COX-2, E-
cadherin, N-cadherin, or SNAI1, or with monoclonal antibodies for β-catenin. Immune positivity 
was revealed by means of appropriate Cy3-conjugated secondary antibody and cells were then 
stained with Hoechst to detect nuclei. After PBS washings, the slides were mounted with 
H2O/glycerol (1:1) and viewed under a fluorescence microscope (Carl Zeiss, Jena, Germany). 
Immunohistochemistry was performed on sections from archived paraffin-included specimens 
obtained from patients with breast cancer diagnosed during the period 2010-2011 in  A.O. Ordine 
Mauriziano, Pathology Unit, Torino, Italy. Briefly, after microwave antigen retrieval, sections (2 
µm thick) were incubated with rabbit polyclonal antibodies against COX-2, E-cadherin, HIF-2α, 
SNAI1 and HO-1 (final dilutions: 1:50, 1:100, 1:100, 1:50 and 1:400, respectively) and then 
incubated with EnVision HRP-labelled (DAKO Corporation, Carpinteria, CA, USA) antibodies 
directed against rabbit antigen [26]. Immunohistochemical reactions were visualized by 3′-
diaminobenzidine tetrahydrochloride as chromogen substrate. Negative controls were performed by 
replacing the respective primary antibodies by isotype- and concentration-matched irrelevant 
antibody. 
3.9 Invasion assay 
Cell invasion was analyzed by employing Boyden chambers equipped with 8 μm porosity 
polyvinylpyrrolidone-free polycarbonate filters that were coated with 50 μg/ml of Matrigel solution. 
The filters were then fixed in ice-cold methanol and stained with crystal violet solution. Cell 
invasion was quantified by counting, with a Zeiss microscope (Oberkochen, Germany) equipped 
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with bright-field optics (400x final magnification), crystal violet-stained cells that invaded Matrigel. 
For each filter, cells in 10 randomly chosen fields were counted and expressed as the number of 
invading cells per high-power field. 
3.10 Zimography 
Analysis of the activity of MMPs was performed on culture medium by means of gelatin 
zymography in 0.1% gelatin-30% acrylamide gels.  Equal amounts of culture medium were loaded 
in each lane properly diluted in Sample Buffer 2X (0.5 M Tris HCl pH 6.8, glycerol, 10% SDS, 
0.1% Bromophenol Blue, distilled water, without β-mercaptoethanol) and the overall procedure was 
performed as previously described [21]. Gelatinolytic activity of MMPs was detected as the clear 
zones of lysis against a blue background. Protein molecular weight marker was also run 
simultaneously with the test samples. Images were digitalized by mean of VersaDoc 4000 and 
analyzed with Quantity One software (Bio-Rad Laboratories, Milano, Italy). 
3.11 Detection of intracellular generation of ROS 
Generation of intracellular ROS was analyzed by the semi-quantitative technique based on the use 
of the 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA). MDA-MB-231 cells were seeded in 
12-well culture plates (10
5
 cells per well). For comparative purposes, cells were treated or not with 
50 µM hydrogen peroxide (H2O2, positive control) for 15 min under normoxic conditions. ROS 
(green fluorescence) has been detected by using the conversion of DCFH-DA (used at 5 μM 
concentration for 15 min) into the corresponding fluorescent derivative [27]. Cells were observed 
and photographed under a Zeiss fluorescence microscope (600x final magnification). 
3.12 Statistical analysis 
Statistical significance of differences between independent groups were analyzed using the one-way 
ANOVA test with Bonferroni post hoc multiple comparisons. All values are expressed as means ± 
SD, and differences were considered significant at p<0.05. 
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4. RESULTS 
4.1 COX-2 expression and prostaglandin production  
MCF-7 human breast tumour cell line, that lacks endogenous COX-2 expression, was transiently 
transfected with either human COX-2 cDNA or the empty vector (controlVECTOR) by employing X-
treme GENE HP DNA transfection reagent, chosen for its high efficiency of transfection and for 
low cytotoxicity (Fig. 1A).  After transfection, the cells were allowed to grow for 48 h, then the 
presence of COX-2 protein was analyzed by western blotting. As shown in Figure 1B, COX-2 
protein level was strongly increased in transfected MCF-7 cells, while the COX-2 band was not 
detectable in control and in controlVECTOR MCF-7 cells. The overexpression of COX-2 was also 
confirmed by indirect immune fluorescence that revealed the appearance of cytoplasmic COX-2 
immune reactivity only in transfected cells  (Fig. 1C). 
In order to obtain a better estimate of the COX-2 protein level and of its enzyme activity, the 
production of the PGE2, the major product of COX-2-initiated arachidonic acid metabolism, was 
measured in the culture medium with an EIA immunoassay. As expected, only COX-2-
overexpressing MCF-7 cells produced high levels of PGE2 whereas its release was negligible in 
both control cells (Fig. 1D) and in controlVECTOR cells (data not shown). These results indicate that 
in transfected cells the overexpressed COX-2 protein is biologically active.   
4.2 EMT features in COX-2- overexpressing cells 
The morphological changes characteristic of cells undergoing EMT are accompanied by a shift in 
gene expression from an epithelial to a mesenchymal repertoire. To determine whether COX-2 
promotes such a shift, both the expression and cellular distribution of selected EMT markers have 
been investigated by western blotting and immune fluorescence.  In COX-2-overexpressing cells, E-
cadherin and β-catenin protein levels are significantly diminished with respect to control and 
controlVECTOR cells (Fig. 2A). Accordingly, positivity for E-cadherin and β-catenin under immune 
fluorescence was similarly reduced in COX-2-overexpressing MCF-7 cells versus parental MCF-7 
cells, then essentially confirming immunoblot findings  (Fig. 2B). Down-regulation of E-cadherin 
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expression in COX-2-overexpressing MCF-7 cells is associated with an increased expression level 
of the transcriptional repressor SNAI1 (Fig. 2A), that is also significantly localized in the nuclei of 
transfected cells  (Fig. 2B). 
Concomitantly, transfected cells presented an increased expression of the mesenchymal markers N-
cadherin and vimentin (Fig. 2A) and again N-cadherin increased expression was confirmed by   
immune fluorescence analysis (Fig. 2B). 
4.3 Roles of MAPK and PI3K/Akt in EMT induction 
The implementation of EMT also depends on the concomitant activity of a variety of signal-
transduction pathways, including ERK/MAPK and PI3K/Akt which, in turn, are also relevant for 
cell proliferation and survival [16]. Therefore, we determined the possible involvement of ERK1/2 
and Akt kinase pathways in COX-2-dependent induction of EMT. Although literature data suggest 
that activation of ERK/MAPK is usually required for a complete EMT in a variety of tumour 
models [17], in transfected MCF-7 cells no significant increase in the level of the phosphorylated 
isoforms of ERK was observed (Fig. 3A). Whether PI3K/Akt pathway is concerned, the expression 
levels of the active form of Akt (p-Akt), the most important downstream effector of PI3K 
signalling, was significantly higher in transfected MCF-7 cells as compared to control and 
controlVECTOR cells (Fig. 3A). Since this signalling component has been described, following 
activation, to phosphorylate and then inhibit GSK3β [28], a critical signalling cross-road in 
maintaining the epithelial phenotype, we evaluated the level of expression of GSK3β in transfected 
MCF-7 cells. Western blotting analysis revealed that COX-2 overexpression resulted in an apparent 
increase of the phosphorylated (inactive) form of GSK3β (Fig. 3A), a scenario which is  known to 
be potentially consistent with the acquisition of mesenchymal morphology.  
4.4 COX-2 modulation of cell invasiveness 
We next evaluated whether COX-2 overexpression might be associated with an increase in cell 
invasiveness. Interestingly, we found that COX-2-overexpressing MCF-7 cells were three-fold more 
invasive than parental cells (Fig. 3B), and the increased invasiveness was accompanied by a 
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relevant increase of matrix metalloproteinase (MMP)-9 release in the culture medium with respect 
to parental cells (Fig. 3C), whereas MMP-2 was undetectable (not shown). MMPs are secreted 
proteolytic enzymes important in promoting invasion through the extracellular matrix. Among 
them, gelatinases MMP-2 and MMP-9 mediate tumour invasion and metastasis through the 
degradation of collagen IV and their overexpression has been associated with a more aggressive 
tumour phenotype.    
4.5 Inhibition of EMT with a COX-2 inhibitor 
Next, we evaluated the role of COX-2 in inducing EMT and then increased invasiveness by an 
alternative experimental approach involving the use of a COX-2 specific inhibitor, celecoxib. 
Accordingly, COX-2-overexpressing MCF-7 cells as well as parental MCF cells were treated with 
celecoxib at 10, 25 and 50 µM concentrations and its effect on cell viability was analyzed. Results 
obtained confirmed our previous findings [4], as in both MCF cells (Fig. 4A) and COX-2-
overexpressing MCF-7 cells (Fig. 4B) the drug can induce a progressive decrease in cell viability, 
with the most relevant effects on cell viability being detected in the presence of 50 µM celecoxib; as 
a consequence, 50 µM celecoxib was not further used in the other experiments. 
When transfected cells were exposed to celecoxib at 10 and 25 µM concentrations in order to 
evaluate effects on selected EMT markers (Fig. 4C), celecoxib was found to result in an apparent 
increase in E-cadherin and β-catenin levels as well as in a reduction of N-cadherin levels as 
compared to transfected only cells.  Remarkably, results shown in Figure 4D indicate that celecoxib 
treatment was also able to reduce cell invasiveness in a dose-dependent fashion, a finding that 
supports the notion that COX-2 overexpression is required to maintain the increased invasive 
potential. Moreover, it should be noted that apparent recovery of epithelial phenotype as well as 
inhibition of invasiveness were already evident in the presence of 10 µM celecoxib, a concentration 
unable to affect viability in either parental or transfected MCF-7 cells.  
4.6 Hypoxia modulation of COX-2 expression and EMT phenotype 
 
12 
A further goal of this study was to investigate whether exposure to hypoxic conditions may affect 
COX-2 expression and the related induction of EMT. For this purpose, parental MCF-7,  COX-2-
overexpressing MCF-7 and COX-2-expressing, highly invasive MDA-MB-231 human breast 
cancer cells were exposed to 3% oxygen for 2 h, 4 h, 8 h and 24 h. 
The intracellular levels of HIF-1α,  evaluated in order to follow the hypoxic response, were similar  
in both parental and transfected MCF-7 cells: HIF-1α levels  were found increased already after 2 h, 
peaked at 4 h and were still higher than those detected under normoxic condition at 8 h and 24 h 
(Fig. 5A,B).  
In parental MCF-7 cells, in which COX-2 is not expressed, changes in HIF-1α levels were 
paralleled by increase of N-cadherin levels (Fig.5A) while COX-2 expression was not induced (data 
not shown). Interestingly, exposure to hypoxic conditions resulted in a further stimulation of COX-
2 expression and in an induction of EMT-related changes in transfected MCF-7 cells, as suggested 
by down-regulation of β-catenin and E-cadherin, and up-regulation of the mesenchymal marker N-
cadherin (Fig. 5B). These changes were also paralleled by significant increase of the invasive ability 
(Fig. 5C) and MMP-9 release (Fig.5D). 
The effects induced by hypoxia were then compared with those detected in COX-2-expressing 
MDA-MB-231 human breast cancer cells. Under normoxic conditions, MDA-MB-231 cells present 
a fibroblastoid-like appearance and are characterised by lack of E-cadherin expression [29] and, at 
the same time, by increased levels of N-cadherin, that is an EMT-related overall 
phenotype/behaviour homologous to the one described in transfected MCF-7 cells. In hypoxic 
condition, MDA-MB-231 cells expressed HIF-1α in a time-dependent manner, as it was increased 
at 2 h, peaked at 4 and 8 h and decreased after 24 h (Fig. 6A). Similarly to the scenario detected in 
transfected MCF-7 cells, HIF-1α level profile was apparently correlated with up-regulation of both 
COX-2 and the mesenchymal marker N-cadherin, as well as with down-regulation of the epithelial 
marker β-catenin (Fig. 6A). Once again, exposure of mesenchymal-like MDA-MB-231 cells to 
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hypoxia resulted in a significant increase of the invasive ability (Fig. 6B) and of MMP-2 and MMP-
9 release in the extracellular medium (Fig.6C). 
4.7 COX-2 modulation of ROS production and heme oxygenase expression 
We next performed experiments in order to investigate whether COX-2 overexpression may be 
critical for intracellular generation of reactive oxygen species (ROS) in human breast cancer cells. 
By employing the DCFH-DA morphological technique, we observed that untreated COX-2-
expressing MDA-MB-231 cells were already characterized by relevant levels of intracellular ROS 
(see positive fluorescence of cells in Fig. 7A), that were not modified by addition of hydrogen 
peroxide in the medium. Of interest, pre-treatment of the same cells with the selective COX-2 
inhibitor celecoxib resulted in a significant inhibition of ROS generation (i.e., significant reduction 
in the number of fluorescent cells). Since these data suggested that COX-2 was significantly 
contributing to intracellular ROS generation, we next analyzed the potential relationships between 
COX-2-related ROS production and the expression of heme oxygenase-1 (HO-1), a cytoprotective 
enzyme with antioxidant activity which is known to be up-regulated in response to increased 
oxidative stress [30]. In agreement with data obtained with DCFH-DA technique, untreated COX-2-
expressing MDA-MB-231 cells were characterized by the presence of readily detectable HO-1 
protein levels. Moreover, HO-1 protein levels, unmodified following exposure to H2O2, were 
drastically reduced in cells pre-treated for 24 h with the selective COX-2 inhibitor celecoxib (Fig. 
7B), thus confirming the involvement of COX-2 in ROS generation.  
4.8 COX-2, E-cadherin,  HIF-2α, SNAI1 and HO-1  tissue expression  
In order to investigate whether data obtained in cell culture may have an in vivo counterpart, we 
next performed immunohistochemistry for COX-2, E-cadherin, HIF-2α, SNAI1 and HO-1 on serial 
sections obtained from either three normal breast tissue specimens or twelve specimens obtained 
from patients with ductal breast cancer (Fig. 8). COX-2 immune positivity, which was detectable at 
low level in normal breast tissue, was found to have a predominant cytoplasmic and perinuclear 
localization in breast cancer epithelial cells, according to previous data from our laboratory [5] and 
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other research groups [31]. By comparing immune histochemical images obtained in normal breast 
tissue and ductal breast cancer, malignant breast cells differed from normal breast epithelial cells 
not only for COX-2-positivity but also for a number of additional significant features, including: a) 
strongly increased positive nuclear staining for the EMT-related transcription factor SNAI1 and the 
hypoxia-related transcription factor HIF-2α; b) significantly decreased positive staining, diffuse in 
the cytoplasm, for E-cadherin, as compared to the very strong positive staining observed in normal 
breast specimens; c) strong positive cytoplasmic staining for HO-1 (absent in epithelial cells of 
normal breast). These morphological observations are consistent with the concept that COX-2-
positive malignant cells in vivo may not only express EMT-related features but may also face 
conditions of tissue hypoxia and intracellular ROS generation. 
 
5. DISCUSSION  
The aim of the present study was to investigate whether changes in COX-2 expression may affect 
epithelial to mesenchymal transition (EMT) and invasive potential of human breast cancer cells. As 
a first approach, we successfully transfected slow growing, non-invasive COX-2 null MCF-7 
human breast tumour cells in order to obtain cancer cells that transiently overexpressed COX-2 and 
to analyse then COX-2 putative role in the modulation of phenotypic features and invasiveness.  
One of the most interesting changes we detected in transfected MCF-7 cells was the apparent loss of 
selected epithelial features and the acquisition of mesenchymal-like phenotypic changes that are 
widely considered as hallmarks of EMT. At first, transfected MCF-7 cells exhibited an increase of 
N-cadherin and vimentin expression accompanied by a reduction of E-cadherin and β-catenin 
levels. E-cadherin is a key member of a family of functionally related transmembrane glycoproteins 
that mediate intercellular adhesion. The cytoplasmic terminal tail of E-cadherin links specifically to 
β-catenin, that, in turn, binds directly to cytoskeletal actin leading to the assembly of cell-cell 
junctions. A loss of E-cadherin expression or function was frequently shown in many different 
types of tumours, where it accompanies the invasiveness and metastatic behaviour of malignant 
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cells [14-16,22,32]. It is well known that down-regulation and relocation of E-cadherin/β-catenin 
complex is critical in the EMT process, leading to β-catenin release from the cell membrane 
followed by accumulation in the cytoplasm and translocation to the nucleus where it promotes cell 
proliferation. These data are consistent with and further expand preliminary data published earlier 
that were suggesting changes into a fibroblastoid morphology and increased vimentin expression in 
MCF-10 cells  stably transfected to overexpress COX-2 [33].  
According to literature data [18], down-regulation of E-cadherin in transfected MCF-7 cells is 
related to the overexpression of SNAI1, a zinc finger transcription factor able to directly repress E-
cadherin expression following its binding to the E-boxes of the human E-cadherin promoter [16,19]. 
Indeed, overexpression of SNAI1 predicts for a more aggressive tumour phenotype [34] and studies 
on breast cancer indicated that SNAI1 overexpression is associated with increased lymph node 
involvement, invasiveness and metastatic potential [35] as well as with decreased recurrence-free 
survival [36] through mechanisms that remains largely unresolved. 
Moreover, SNAI1 up-regulation detected in transfected MCF-7 cells is likely to be related to the 
increase of the phosphorylated form (i.e., inactive form) of GSK3β. Accumulating literature 
evidences indicate that GSK3β activity is critical in maintaining the epithelial phenotype, with  
GSK3β-dependent SNAI1 binding and phosphorylation facilitating its proteasomal degradation 
[32,37,38]. Accordingly, inhibition of GSK3β upon phosphorylation can promote the stabilization 
and the nuclear translocation of SNAI1, and the subsequent induction of EMT [16,32,39].  
Concerning mechanisms able to relate COX-2 overexpression and EMT, recent reports [40] indicate 
that COX-2/PGE2 pathway may be responsible for activation of both PI3K/Akt and ERK1/2 
pathways via the prostaglandin EP4 receptor, thus resulting in increased growth, motility, and 
resistance to apoptosis of cancer cells. Data in this study, however, indicate that in COX-2-
overexpressing MCF-7 cells only the levels of phospho-Akt were up-regulated whereas no apparent 
increase of phosphorylated (i.e., active) ERK1/2 isoforms was detected. This is consistent with 
literature data [41,42] indicating that PI3K/Akt signalling plays a prominent role in inducing and 
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maintaining EMT and also suggest that in transfected MCF-7 cells overexpression of COX-2, 
through activation of PI3K/Akt, can result in the reduction of the active form of GSK3ß and 
modulation of EMT-related signals, including up-regulation of SNAI1 and consequent repression of 
E-cadherin gene transcription and EMT induction. This interpretation is sustained by the following 
major findings and considerations: a) transfected MCF-7 cells exhibited a more invasive phenotype 
with respect to parental cells and possessed extracellular matrix degrading activity that was likely 
due to the release of the matrix metalloproteinase 9; b) the overall phenotype of transfected MCF-7 
cells was consistent with the one exhibited by the more aggressive and invasive MDA-B231 cells, 
which are known to normally overexpress COX-2; c) EMT related changes and increased 
invasiveness were at least partly prevented by pre-treatment of COX-2 expressing human breast 
cells with celecoxib,  a well known selective COX-2 inhibitor.    
Whether the critical role of COX-2 in EMT induction from a mechanistic point of view is 
concerned, current literature offers a number of inter-related and established concepts. First,  COX-
2  has been suggested to be up-regulated in colorectal and lung cancer cells by hypoxic conditions 
through HIF-1-dependent mechanisms [14,23,24], and that such an induction can enhance cell 
motility and invasiveness. This is potentially relevant since the presence of hypoxic areas within the 
neoplastic mass represents a major and common feature of clinically relevant solid malignant 
tumours  [43]. Moreover, hypoxia is currently believed to provide a strong selective pressure able to 
eventually favour proliferation and survival of the most aggressive malignant cells and the detection 
of hypoxic areas within a neoplastic mass is considered an independent prognostic indicator of poor 
outcome with a significant risk to develop metastasis that may escape therapy [12,44]. Relevant to 
this study, hypoxia has also been shown to trigger epithelial-to-mesenchymal transition (EMT) in 
human malignant cancer cells of different origin [21]. Along these lines, in the present study we 
were able to confirm that exposure of COX-2-overexpressing MCF-7 and COX-2 expressing, 
highly invasive MDA-MB-231 human breast cancer cells to hypoxia resulted in a further (i.e., two 
fold) increase in the expression of COX-2 protein as well as in an exacerbation of typical EMT-
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related changes (down regulation of β-catenin, up-regulation of N-cadherin) coupled to increased 
release of MMPs and overall invasive ability. These results then corroborate the relevant additional 
concept that hypoxic conditions can effectively enhance COX-2 expression levels and through this 
event further promote EMT induction and invasiveness. Such a scenario is compatible with results 
obtained by immunohistochemistry performed on thin serial sections obtained from normal breast 
tissue and breast cancer specimens (Fig. 8). This morphological analysis showed that malignant 
epithelial cells of ductal breast cancer were characterized by positive immune-staining for COX-2 
as well as by changes consistent with ongoing EMT (decreased staining for E-cadherin and 
increased nuclear staining for SNAI1). Moreover, epithelial breast cancer cells but not epithelial 
cells in normal breast, showed cytoplasmic immune positivity for HO-1 as well as a very  
significant increase in nuclear positivity for HIF-2α. Taken together, these data  suggest  that in vivo 
COX-2-positive cells were likely not only to express EMT-related features but also to face 
conditions of tissue hypoxia and intracellular reactive oxygen species (ROS) generation. These data 
are also consistent with previous results suggesting the existence of a statistically significant 
association between COX-2 and human breast cancer-related clinic-pathological parameters 
associated with poor prognosis, such as size, grading, extent of primary tumor, nodal status and 
vascular invasion [5].   
A final relevant concept should be recalled that may further interconnect COX-2 and hypoxia.  
COX-2 up-regulation during hypoxia has been associated with an increase in PGE2 levels [24] and 
the latter has been proposed to play a role in the promotion of cell survival under hypoxic 
conditions, critical for tumour cells to propagate and progress [12]. Recent studies reported that 
activation of COX-2 led to increased intracellular generation of ROS mechanistically linked to 
EMT induction in prostate cancer cells, an event efficiently prevented by either antioxidant 
treatment or by COX-2 silencing [45,46,47].   
The possible critical role of ROS generated by COX-2 has been revealed in the present study 
concerning human breast cancer cells. Indeed, COX-2 expressing MDA-MB-231 cells produced 
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abundant levels of ROS, which were significantly reduced by the selective COX-2 inhibitor 
celecoxib. Accordingly, celecoxib pre-treatment was also able to down-regulate the expression of 
the redox-sensitive enzyme HO-1, which is overexpressed in untreated MDA-MB-231 cells (this 
study) as well as in other cancer cells [30]. In keeping with a critical role of ROS released by COX-
2, our results suggest that COX-2 up-regulation can contribute to ROS generation in breast cancer 
cells. Furthermore, since celecoxib was reported in our study to prevent EMT changes and 
invasiveness related to COX-2 expression, it is conceivable that COX-2-related induction of EMT 
and enhancement of cancer cell invasiveness may significantly depend also on COX-2-dependent 
intracellular production of ROS. 
According to this hypothesis, a recent report highlighted that cancer-associated macrophages 
(CAM), through a IL-1β-dependent and ROS-mediated induction of COX-2 expression in 
HCC1954 breast cancer cells, resulted in an enhancement in their aggressiveness [48]. Although 
EMT was not specifically investigated, the data from the latter study suggest than that also stimuli 
released from cancer associated macrophages may contribute to COX-2 expression again in a 
redox-related way.  
5.1 Conclusions 
COX-2 up-regulation has been reported in a number of different tumour types [49], and there has 
been a great deal of interest in attempting to achieve additional understanding of the regulatory 
networks that control COX-2-related effects. In this scenario, the results obtained in our study 
allowed to gain additional insights into the biological roles of COX-2 in human breast cancer cell 
behaviour suggesting a direct link between COX-2 overexpression and invasive ability. COX-2-
related induction of EMT and increased invasiveness in breast cancer cells, as proposed from a 
recent study in prostate cancer cells, is likely to be also significantly related to COX-2-dependent 
intracellular generation of ROS, a scenario which is likely to be emphasized by either hypoxic 
conditions or other signals (growth factors, cyto- and chemokines) from cancer microenvironment 
(Fig. 9).   
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Future studies into the emerging players within the COX-2/PGE2 pathway may reveal novel 
approaches for more safely targeting this pathway for both cancer chemoprevention and therapy.  
 
6. DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST 
Authors involved in the present study have no potential conflicts of interest to disclose and they 
have received no payment in preparation of this manuscript. The financial support was received 
from University of Torino, Torino, Italy.  
 
 
20 
 7. REFERENCES 
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin  2008;58:71-96. 
2. Wiwanitkit V. Combination of EGFR and COX-2 inhibitors in breast cancer patient. 
Tumour Biol 2012;33:1261.  
3. Park BW, Park S, Park HS, et al. Cyclooxygenase-2 expression in proliferative Ki-67-
positive breast cancers is associated with poor outcomes. Breast Cancer Res Treat 
2012;133:741-751.  
4. Bocca C, Bozzo F, Bassignana A, et al. Antiproliferative effects of COX-2 inhibitor 
celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011;350:59-70.  
5. Miglietta A, Toselli M, Ravarino N, et al. COX-2 expression in human breast carcinomas: 
correlation with clinicopathological features and prognostic molecular markers. Expert Opin 
Ther Targets 2010;14:655-664. 
6. Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 2002;108:173-179. 
7. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the 
colon, breast, prostate, and lung. Inflammopharmacology 2009;17:55-67. 
8. Imada T, Matsuoka J, Nobuhisa T, et al. COX-2 induction by heparanase in the progression 
of breast cancer. Int J Mol Med 2006;17:221-228. 
9. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: 
review. Breast Cancer Res Treat 2008;109:189-198.*Relevant review outlining COX-2 
expression as a fundamental step in breast cancer pathogenesis  
10. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 
2001;411:375-379. 
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–732. 
12. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer 
Metastasis Rev 2007;26:225-239. 
 
21 
13. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and 
molecular aspects. J Natl Cancer Inst 2001;93:266-276. *Relevant review summarizing 
the fundamental role for hypoxia in the progression of solid tumors 
14. Bocca C, Bozzo F, Cannito S, et al. Celecoxib inactivates epithelial-mesenchymal transition 
stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Mol Carcinog 
2012;51:783-795. 
15. Jiang J, Tang YL, Liang XH.  EMT: a new vision of hypoxia promoting cancer progression. 
Cancer Biol Ther 2011;11:714-723. 
16. Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer 
cells. Semin Cancer Biol 2012;22:194-207.  
17. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and 
contribution of tumor microenvironment.  J Cell Biochem 2007;101:816-829. 
18. Foroni C, Broggini M, Generali D, et al. Epithelial-mesenchymal transition and breast 
cancer: role, molecular mechanisms and clinical impact. Cancer Treat Res 2012;38:689-697. 
**Relevant study focusing on the physiological and pathological role of EMT process, 
its molecular related network, its putative role in the metastatic process and its 
implications in response/resistance to the current and/or new approaching drugs in the 
clinical management of breast cancer. 
19. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development 
and disease. Cell 2009;139:871-890. 
20. Lundgren K, Nordenskjöld B, Landberg G. Hypoxia, Snail and incomplete epithelial-
mesenchymal transition in breast cancer. Br J Cancer 2009;101:1769-1781. 
21. Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent 
epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008;29:2267-2278.  
22. Cannito S, Novo E, di Bonzo LV, et al. Epithelial-Mesenchymal Transition: From 
Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease. 
 
22 
Antioxid Redox Signal 2010;12:1383-1430. *Relevant review summarising the major 
relevant features of EMT and the signaling mechanisms that are known to regulate or 
affect the process, including the role for oxidative stress and reactive oxygen species 
(ROS) 
23. Csiki I, Yanagisawa K, Haruki N, et al. Thioredoxin-1 modulates transcription of 
cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer 
Res 2006;66:143-150. 
24. Kaidi A, Qualtrough D, Williams AC, et al. Direct transcriptional up-regulation of 
cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell 
survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 
2006;66:6683-6691.*Relevant study outlining COX-2 as a direct target for HIF-1 in 
colorectal tumor cells, with implication for cancer cell survival and angiogenesis  
25. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and-2 in two 
human breast cancer cell lines. Cancer Res 1996;56:5125-5127. 
26. Novo E, Povero D, Busletta C, et al. The biphasic nature of hypoxia-induced directional 
migration of activated human hepatic stellate cells. J Pathol 2012;226:588-597. 
27. Rezvani HR, Dedieu S, North S, et al. Hypoxia inducible factor 1α, a key factor in the 
keratinocyte response to UVB exposure. J Biol Chem 2007;282:16413-16422. 
28. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends 
Biochem Sci 2004;29:95-102. 
29. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during 
mesenchymal to epithelial reverting transition. Mol Cancer 2010;9:179-197. 
30. Grochot-Przeczek A, Dulak J, Jozkowicz A. Haem oxygenase-1: non-canonical roles in 
physiology and pathology. Clin  Sci (Lond) 2012;122:93-103. 
 
23 
31. Maroni P, Matteucci E, Luzzati A, et al. Nuclear co-localization and functional interaction 
of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma. Breast 
Cancer Res Treat 2011;129:433-450.  
32. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, 
and clinical considerations. Cancer Metastasis Rev 2012;31:277-283.  
33. Lu S, Yu G, Zhu Y, et al. Cyclooxygenase-2 overexpression in MCF-10F human breast 
epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial 
transformation. In J Cancer 2005;116:847-852. 
34. Francí C, Gallén M, Alameda F, et al. Snail1 protein in the stroma as a new putative 
prognosis marker for colon tumours. PLoS One 2009;4:e5595. 
35. Blanco MJ, Moreno-Bueno G, Sarrio D, et al. Correlation of Snail expression with 
histological grade and lymph node status in breast carcinomas. Oncogene 2002;21:3241-
3246. 
36. Moody SE, Perez D, Pan TC, et al. The transcriptional repressor snail promotes mammary 
tumor recurrence. Cancer Cell 2005;8:197-209.*Relevant clinical study that outlines that 
Snail expression levels are sufficient to promote mammary tumor recurrence in vivo, 
and that high levels of Snail predict decreased relapse-free survival in women with 
breast cancer 
37. Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-
mesenchymal transitions. Cells Tissues Organs 2007;185:73-84. 
38. Acloque H, Adams MS, Fishwick K, et al. Epithelial-mesenchymal transitions: the 
importance of changing cell state in development and disease. J Clin Invest 2009;119:1438-
1449. 
39. Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3beta-mediated 
phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6:931-
940. 
 
24 
40. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the 
hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 
2009;30:377-386. *Relevant study focusing on the emerging regulators of COX–
prostaglandin signaling and novel roles for COX-2/PGE2 signaling in the tumour 
microenvironment. 
41. Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for 
ErbB3-driven breast cancer cell motility and metastasis. Oncogene 2012;31:706-715.  
42. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 Induces Hypoxia-inducible Factor-
1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line. J Biol 
Chem 2002;277:50081-50086. 
43. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med 2007;85:1301-
1307. 
44. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death 
& Differ 2008;15:678-685. 
45. Giannoni E, Parri M, Chiarugi P. EMT and oxidative stress: a bidirectional interplay 
affecting tumor malignancy. Antioxid Redox Signal 2012;16:1248-1263. *Relevant review 
outlining the concept that intracellular ROS may regulate EMT through a mechanism 
involving HIF-1 and COX-2. 
46. Giannoni E, Bianchini F, Masieri L, et al.  Reciprocal activation of prostate cancer cells and 
cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer 
stemness. Cancer Res 2010;70:6945-6956. 
47. Giannoni E, Bianchini F, Calorini L, et al. Cancer associated fibroblasts exploit reactive 
oxygen species through a proinflammatory signature leading to epithelial mesenchymal 
transition and stemness. Antioxid Redox Signal 2011;14:2361-2371.  
48. Hou Z, Falcone DJ, Subbaramaiah K, et al. Macrophages induce COX-2 expression in breast 
cancer cells: Role of IL-1beta autoamplification. Carcinogenesis 2011;32:695-702. 
 
25 
49. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer 
prevention and treatment. Trends Pharmacol Sci 2003;24:96-102. 
 
26 
8. TITLES AND LEGENDS TO FIGURES 
FIGURE 1: COX-2 expression, subcellular localization and activity. 
MCF-7 cells were transiently transfected by employing X-treme GENE HP DNA transfection 
reagent.   
A: Cell viability was assessed by the trypan blue exclusion test after 48 h from the transfection. 
Results are expressed as viable cell number/ml and represent mean ± S.D. of three independent 
experiments, each performed in triplicate.  
B: COX-2 protein expression levels were analyzed by western blotting. Total cell lysates were 
incubated with polyclonal antibody for COX-2 and then with HRP-conjugated secondary antibody. 
The blot shown is representative of three independent experiments. 
C: COX-2 immune reactivity was detected in MCF-7 cells exposed to anti-COX-2 polyclonal 
primary antibody followed by anti-mouse Cy3-conjugated secondary antibody. To detect nuclei the 
cells were stained with Hoechst. The images show the overlaid pictures (400× final magnification) 
and are representative of three independent experiments.  
D: COX-2 activity was detected by measuring the amounts of PGE2 in cell culture medium as 
described in Materials and Methods. Data are expressed as pg/ml PGE2 and represent mean ± S.D. 
of three independent experiments, each performed in triplicate.  
 
FIGURE 2: Expression and subcellular localization of EMT markers in MCF-7 cells under 
normoxic condition. 
A: Total cell lysates were analyzed by western blotting to determine the expression levels of E-
cadherin, β-catenin, N-cadherin, vimentin and SNAI1. The optical density of the bands was 
determined by densitometry, normalized with respect to that of the corresponding β-actin band and 
expressed as arbitrary units relative to the control (S.D. < 10%). The data are representative of three 
independent experiments.  
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B: The cells were fixed and exposed to anti-E-cadherin, β-catenin, N-cadherin and SNAI1 primary 
antibody followed by proper Cy3-conjugated secondary antibody. To detect nuclei the cells were 
stained with Hoechst. The images show the overlaid pictures (400× final magnification) and are 
representative of three independent experiments.  
 
FIGURE 3: Analysis of COX-2 related signaling pathway and invasive ability. 
A: Total cell lysates were analyzed by western blotting to determine the expression levels of p-Akt 
p-ERK1/2 and p-GSK3β. The optical density of the bands was determined by densitometry, 
normalized with respect to that of the corresponding Akt,  ERK1/2  or β-actin band and expressed 
as arbitrary units relative to the control (S.D. < 10%). The data are representative of three 
independent experiments.  
B: Matrigel invasion was evaluated by employing Boyden chamber’s assay; each filter was 
examined with a Zeiss microscope (400x final magnification) and the number of cells able to invade 
the matrigel was counted. Data are expressed as the number of
 
cells per high-magnification field 
and represent the mean of three independent experiments, each performed in triplicate (bars, S.D.). 
*p<0.01 versus values in MCF-7 parental cells (control). 
C: MMP-9 release was determined by gelatin zymography of cell-free supernatants obtained from 
MCF-7 cells maintained for 24 h under normoxic condition. The zymogram shown is representative 
of three independent experiments. Gelatinase activity was estimated by densitometry and expressed 
as arbitrary units relative to normoxic control (S.D. < 10%).  
 
FIGURE 4:  Effect of celecoxib on cell viability, EMT induction and invasive ability. 
Control and transfected MCF-7 cells were incubated for 24 h in the absence or in the presence of 
celecoxib at the indicated concentrations.  
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A,B: Cell viability was assessed by the trypan blue exclusion test in control (A) and transfected (B) 
MCF-7 cells. Results are expressed as number of viable cells/ml and values represent mean ± S.D. 
of three independent experiments, each performed in triplicate.  
* p<0.05, ** p<0.001  versus values in respective control. 
C: Total cell lysates were analyzed by western blotting to determine levels of COX-2, E-cadherin, 
ß-catenin and N-cadherin. The optical density of the bands was determined by densitometry, 
normalized with respect to that of the corresponding -actin band and expressed as arbitrary units 
relative to the control (S.D. < 10%). The data are representative of three independent experiments.  
D: Matrigel invasion was evaluated by employing Boyden chamber’s assay; each filter was 
examined with a Zeiss microscope (400x final magnification)  and the number of cells able to 
invade the matrigel was counted. Data are expressed as the number of
 
cells per high-magnification 
field and represent the mean of three independent experiments, each performed in triplicate (bars, 
S.D.).  
*p<0.001 versus values in control cells; 
§
p<0.05, 
§§
p<0.01 versus values in transfected cells 
 
FIGURE 5:  Effect of hypoxia on EMT induction and invasive ability in control and transfected 
MCF-7 cells. 
A, B: Control (A) and transfected (B) MCF-7 cells were incubated for 0 h (control), 2 h, 4 h, 8 h 
and 24 h under hypoxic conditions. Total cell lysates were analyzed by western blotting to 
determine levels of HIF-1α, β-catenin, E-cadherin, N-cadherin and COX-2. The optical density of 
the bands was determined by densitometry, normalized with respect to that of the corresponding β-
actin band and expressed as arbitrary units relative to the control (S.D. < 10%). The data are 
representative of three independent experiments.  
C: Control and transfected MCF-7 cells were incubated for 24 h under hypoxic conditions. Matrigel 
invasion was evaluated by employing Boyden chamber’s assay; each filter was examined with a 
Zeiss microscope (400x final magnification)  and the number of cells able to invade the matrigel 
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was counted. Data are expressed as the number of
 
cells per high-magnification field and represent 
the mean of three independent experiments, each performed in triplicate (bars, S.D.). *p<0.01 
versus values in normoxic control cells. 
D: Control and transfected MCF-7 cells were incubated for 24 h under normoxic and hypoxic 
conditions. MMP-9 release was determined by gelatin zymography of cell-free supernatants. The 
zymograms shown are representative of three independent experiments. Gelatinase activity was 
estimated by densitometry and expressed as arbitrary units relative to normoxic control (S.D. < 
10%). 
 
FIGURE 6:  Effect of hypoxia on EMT induction and invasive ability in MDA-MB-231 cells. 
A: MDA-MB-231 cells were incubated for 0 h (control), 2 h, 4 h, 8 h and 24 h under hypoxic 
conditions. Total cell lysates were analyzed by western blotting to determine levels of HIF-1α, 
COX-2, β-catenin and N-cadherin. The optical density of the bands was determined by 
densitometry, normalized with respect to that of the corresponding β-actin band and expressed as 
arbitrary units relative to the control (S.D. < 10%). The data are representative of three independent 
experiments. 
B: The cells were incubated for 24 h under normoxic and hypoxic conditions. Matrigel invasion was 
evaluated by employing Boyden chamber’s assay; each filter was examined with a Zeiss 
microscope (400x final magnification) and the number of cells able to invade the matrigel was 
counted. Data are expressed as the number of
 
cells per high-magnification field and represent the 
mean of three independent experiments, each performed in triplicate (bars, S.D.).  
*p<0.01 versus values in normoxic control cells. 
C: The cells were incubated for 24 h under normoxic and hypoxic conditions. MMP-2 and -9 
release was determined by gelatin zymography of cell-free supernatants. The zymograms shown are 
representative of three independent experiments. Gelatinase activity was estimated by densitometry 
and expressed as arbitrary units relative to normoxic control (S.D. < 10%).  
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FIGURE 7. Intracellular generation of ROS and heme oxygenase-1 expression in MDA-MB-231 
cells. 
A: Generation of intracellular ROS was detected by the semi-quantitative technique based on the 
use of 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) in MDA-MB-231 control cells, in 
MDA-MB-231 cells treated for 15 min with 50 μM H2O2 (positive control) and in MDA-MB-231 
cells exposed for 4 h to celecoxib  at 10 and 25 µM concentrations. For any condition, the image is 
obtained by digital overlay of phase contrast image with DCFH-DA positive image. Data in bar 
graph are expressed as number of fluorescent cells for field and represent the mean ± S.D. of three 
independent experiments. *p<0.01 versus values in control cells. 
B: Heme oxygenase-1 expression was analyzed by western blotting. MDA-MB-231 cells were 
treated or not for 30 min with 50 µM H2O2 (positive control) or with celecoxib for 24 h at 10 and 25 
µM concentrations. Total cell lysates were incubated with polyclonal antibody for HO-1 followed 
by HRP-conjugated secondary antibody. The optical density of the bands was determined by 
densitometry, normalized with respect to that of the corresponding β-actin band and expressed as 
arbitrary units relative to the control (S.D. < 10%). The data are representative of three independent 
experiments.  
 
FIGURE 8. Expression of COX-2, EMT markers and heme oxygenase-1 in normal breast tissue 
and ductal breast cancer (G2, score 7, Elston-Ellis).  
Immunohistochemical analysis was performed on serial sections from paraffin-included normal 
(n=3) breast tissues and breast cancer (n=12) specimens using rabbit polyclonal antibodies against 
COX-2, E-cadherin, HIF-2α, SNAI1 and HO-1. Immunohistochemical reactions were visualized by 
3′-diaminobenzidine tetrahydrochloride as chromogen substrate. Nuclei were counterstained with 
hematoxylin. Original magnification as indicated.  
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FIGURE 9. Schematic representation of the COX-2-related mechanisms potentially leading to 
mesenchymal morphology in breast cancer cells. COX-2 overexpression, further enhanced by 
hypoxia, can induce generation of ROS leading to activation of the PI3K/Akt signaling pathway. 
Activated Akt may cause the inactivation of GSK3β by phosphorylation, which, in turn, can favor 
translocation of SNAI1 to the nucleus where it functions as a repressor of E-cadherin and then 
initiates EMT. Celecoxib, as a specific COX-2 inhibitor, can negatively affect EMT induction.   
 
